1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Non-Alcoholic Steatohepatitis Market
2.2. Global Non-Alcoholic Steatohepatitis Market, By Drug, 2023 (US$ Million)
2.3. Global Non-Alcoholic Steatohepatitis Market, By Geography, 2023 (US$ Million)
2.4. Attractive Investment Proposition by Geography, 2023

3. Non-Alcoholic Steatohepatitis Market: Competitive Analysis
3.1. Market Positioning of Key Non-Alcoholic Steatohepatitis Market Vendors
3.2. Strategies Adopted by Non-Alcoholic Steatohepatitis Market Vendors
3.3. Key Industry Strategies
4. Non-Alcoholic Steatohepatitis Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Non-Alcoholic Steatohepatitis Market Value, 2022 - 2032, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
4.6. Porter's Five Force Model
4.6.1. Supplier Power
4.6.2. Buyer Power
4.6.3. Threat Of Substitutes
4.6.4. Threat Of New Entrants
4.6.5. Competitive Rivalry
4.7. PESTEL Analysis
4.7.1. Political Landscape
4.7.2. Economic Landscape
4.7.3. Technology Landscape
4.7.4. Legal Landscape
4.7.5. Social Landscape

5. Non-Alcoholic Steatohepatitis Market: By Drug, 2022-2032, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2023 Versus 2032
5.3. Market Segmentation
5.3.1. Obeticholic Acid
5.3.2. Aramchol
5.3.3. Saroglitazar
5.3.4. Elafibranor


6. North America Non-Alcoholic Steatohepatitis Market, 2022-2032, USD (Million)
6.1. Market Overview
6.2. Non-Alcoholic Steatohepatitis Market: By Drug, 2022-2032, USD (Million)
6.3.Non-Alcoholic Steatohepatitis Market: By Region, 2022-2032, USD (Million)
6.3.1.North America
6.3.1.1. U.S.
6.3.1.1.1. Non-Alcoholic Steatohepatitis Market: By Drug, 2022-2032, USD (Million)
6.3.1.2. Canada
6.3.1.2.1. Non-Alcoholic Steatohepatitis Market: By Drug, 2022-2032, USD (Million)
6.3.1.3. Rest of North America
6.3.1.3.1. Non-Alcoholic Steatohepatitis Market: By Drug, 2022-2032, USD (Million)

7. UK and European Union Non-Alcoholic Steatohepatitis Market, 2022-2032, USD (Million)
7.1. Market Overview
7.2. Non-Alcoholic Steatohepatitis Market: By Drug, 2022-2032, USD (Million)
7.3.Non-Alcoholic Steatohepatitis Market: By Region, 2022-2032, USD (Million)
7.3.1.UK and European Union
7.3.1.1. UK
7.3.1.1.1. Non-Alcoholic Steatohepatitis Market: By Drug, 2022-2032, USD (Million)
7.3.1.2. Germany
7.3.1.2.1. Non-Alcoholic Steatohepatitis Market: By Drug, 2022-2032, USD (Million)
7.3.1.3. Spain
7.3.1.3.1. Non-Alcoholic Steatohepatitis Market: By Drug, 2022-2032, USD (Million)
7.3.1.4. Italy
7.3.1.4.1. Non-Alcoholic Steatohepatitis Market: By Drug, 2022-2032, USD (Million)
7.3.1.5. France
7.3.1.5.1. Non-Alcoholic Steatohepatitis Market: By Drug, 2022-2032, USD (Million)
7.3.1.6. Rest of Europe
7.3.1.6.1. Non-Alcoholic Steatohepatitis Market: By Drug, 2022-2032, USD (Million)

8. Asia Pacific Non-Alcoholic Steatohepatitis Market, 2022-2032, USD (Million)
8.1. Market Overview
8.2. Non-Alcoholic Steatohepatitis Market: By Drug, 2022-2032, USD (Million)
8.3.Non-Alcoholic Steatohepatitis Market: By Region, 2022-2032, USD (Million)
8.3.1.Asia Pacific
8.3.1.1. China
8.3.1.1.1. Non-Alcoholic Steatohepatitis Market: By Drug, 2022-2032, USD (Million)
8.3.1.2. Japan
8.3.1.2.1. Non-Alcoholic Steatohepatitis Market: By Drug, 2022-2032, USD (Million)
8.3.1.3. India
8.3.1.3.1. Non-Alcoholic Steatohepatitis Market: By Drug, 2022-2032, USD (Million)
8.3.1.4. Australia
8.3.1.4.1. Non-Alcoholic Steatohepatitis Market: By Drug, 2022-2032, USD (Million)
8.3.1.5. South Korea
8.3.1.5.1. Non-Alcoholic Steatohepatitis Market: By Drug, 2022-2032, USD (Million)
8.3.1.6. Rest of Asia Pacific
8.3.1.6.1. Non-Alcoholic Steatohepatitis Market: By Drug, 2022-2032, USD (Million)

9. Latin America Non-Alcoholic Steatohepatitis Market, 2022-2032, USD (Million)
9.1. Market Overview
9.2. Non-Alcoholic Steatohepatitis Market: By Drug, 2022-2032, USD (Million)
9.3.Non-Alcoholic Steatohepatitis Market: By Region, 2022-2032, USD (Million)
9.3.1.Latin America
9.3.1.1. Brazil
9.3.1.1.1. Non-Alcoholic Steatohepatitis Market: By Drug, 2022-2032, USD (Million)
9.3.1.2. Mexico
9.3.1.2.1. Non-Alcoholic Steatohepatitis Market: By Drug, 2022-2032, USD (Million)
9.3.1.3. Rest of Latin America
9.3.1.3.1. Non-Alcoholic Steatohepatitis Market: By Drug, 2022-2032, USD (Million)

10. Middle East and Africa Non-Alcoholic Steatohepatitis Market, 2022-2032, USD (Million)
10.1. Market Overview
10.2. Non-Alcoholic Steatohepatitis Market: By Drug, 2022-2032, USD (Million)
10.3.Non-Alcoholic Steatohepatitis Market: By Region, 2022-2032, USD (Million)
10.3.1.Middle East and Africa
10.3.1.1. GCC
10.3.1.1.1. Non-Alcoholic Steatohepatitis Market: By Drug, 2022-2032, USD (Million)
10.3.1.2. Africa
10.3.1.2.1. Non-Alcoholic Steatohepatitis Market: By Drug, 2022-2032, USD (Million)
10.3.1.3. Rest of Middle East and Africa
10.3.1.3.1. Non-Alcoholic Steatohepatitis Market: By Drug, 2022-2032, USD (Million)

11. Company Profile
11.1. AstraZeneca plc
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Product Portfolio
11.1.4. Strategic Initiatives
11.2. Intercept Pharmaceutical Inc.
11.2.1. Company Overview
11.2.2. Financial Performance
11.2.3. Product Portfolio
11.2.4. Strategic Initiatives
11.3. Galmed Pharmaceuticals
11.3.1. Company Overview
11.3.2. Financial Performance
11.3.3. Product Portfolio
11.3.4. Strategic Initiatives
11.4. GENFIT SA
11.4.1. Company Overview
11.4.2. Financial Performance
11.4.3. Product Portfolio
11.4.4. Strategic Initiatives
11.5. Allergan
11.5.1. Company Overview
11.5.2. Financial Performance
11.5.3. Product Portfolio
11.5.4. Strategic Initiatives
11.6. Gilead Science Inc.
11.6.1. Company Overview
11.6.2. Financial Performance
11.6.3. Product Portfolio
11.6.4. Strategic Initiatives
11.7. Zydus Cadila
11.7.1. Company Overview
11.7.2. Financial Performance
11.7.3. Product Portfolio
11.7.4. Strategic Initiatives
11.8. Immuron Ltd.
11.8.1. Company Overview
11.8.2. Financial Performance
11.8.3. Product Portfolio
11.8.4. Strategic Initiatives
11.9. Conatus Pharmaceuticals
11.9.1. Company Overview
11.9.2. Financial Performance
11.9.3. Product Portfolio
11.9.4. Strategic Initiatives
11.10. Novo Nordisk
11.10.1. Company Overview
11.10.2. Financial Performance
11.10.3. Product Portfolio
11.10.4. Strategic Initiatives
11.11. Enzo Biochem, Inc.
11.11.1. Company Overview
11.11.2. Financial Performance
11.11.3. Product Portfolio
11.11.4. Strategic Initiatives
11.12. Raptor Pharmaceuticals
11.12.1. Company Overview
11.12.2. Financial Performance
11.12.3. Product Portfolio
11.12.4. Strategic Initiatives